Skip to content

Pilot Study Describing the Early Evolution of the Sexual Function of Patients Receiving Adjuvant Hormone Therapy for Breast Cancer

Pilot Study Describing the Early Evolution of the Sexual Function of Patients Receiving Adjuvant Hormone Therapy for Breast Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03395327
Enrollment
50
Registered
2018-01-10
Start date
2018-02-20
Completion date
2020-05-15
Last updated
2019-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The 2014-2019 cancer plan emphasizes the need to reduce the impact of cancer on personal life. The impact of cancer on sexuality is multifactorial: fatigue, anxiety, impaired body image, chemotherapy treatment. None of these studies specifically assessed the early impact on the quality of sexual life of patients. The purpose of this study is to describe to describe the early evolution of the quality of sexual life of patients receiving adjuvant hormone therapy for breast cancer.

Interventions

OTHERquality of life questionnaire

QLQ-C30 and BR23 (Quality of Life Questionnaire and Breast 23) Questionnaire FSFI (Female Sexual Function Index)

Sponsors

Centre Hospitalier Departemental Vendee
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age greater than or equal to 18 years * Female gender * Histologically proven non-metastatic breast cancer * Indication of adjuvant hormone therapy * Patient able to understand a newsletter and to agree to participate

Exclusion criteria

* Age under 18 years * Pregnant woman * Adjuvant chemotherapy * Patient followed for heavy psychiatric pathology (requiring guardianship or trusteeship) * Persons protected or deprived of their liberty * Male

Design outcomes

Primary

MeasureTime frame
score FSFI (Female Sexual Function Index)3 month after adjuvant hormone therapy

Countries

France

Contacts

Primary ContactLucie AUZANNEAU
lucie.auzanneau@chd-vendee.fr02 51 44 63 80

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026